关键数据
1.210今开
1.230最高
59.85K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.06%换手率
1.180昨收
1.190最低
72.25K成交额
亏损市盈率静
0.80市净率
0.00%股息率 TTM
-18.43%ROA
1.86552周最高
67.77量比
-41.05M净利润
106.13M总股本
-0.3669每股收益TTM
1.21Beta
-21.30%ROE
0.64352周最低
3.39%振幅
69.19%毛利率
126.83M总市值
3.05回报/风险
4.37%风险率

即将为您带来更多新闻,敬请期待。。。
MaxCyte Inc评分
0.07与上次评分对比预测8.67
财务诊断6.36
技术分析4.36
公司估值7.96
机构认同度7.00
风险评估2.80
分析师评级
买入评级
4.107目标均价
+245.17%涨幅空间
MaxCyte Inc 最新财报电话会记录
MaxCyte (MXCT) 2026财年第二季度业绩电话会议:随着与基因泰克合作扩大重申业绩指引
MaxCyte 2026财年第二季度营收下降15%至730万美元,同时成本有所下降,公司维持了2026财年业绩指引。基因泰克(Genentech)和DTx将支撑下半年的增长。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
MaxCyte Inc 简介
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
行业医疗设备与耗材
公司代码MXCT
员工数量114
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| Capricorn Fund Managers Ltd | 7.65% |
|---|
| BlackRock Institutional Trust Company, N.A. | 6.96% |
|---|
| River Global Investors LLP | 5.13% |
|---|
| Vitruvian Partners LLP | 4.71% |
|---|
| 股东类型 | 占比 |
|---|
| Investment Advisor | 28.60% |
|---|
| Investment Advisor/Hedge Fund | 20.75% |
|---|
| Hedge Fund | 8.15% |
|---|
| Private Equity | 4.71% |
|---|
常见问题
MaxCyte Inc(MXCT)的当前股价是多少?
MaxCyte Inc(MXCT)的当前股价是 1.20。
MaxCyte Inc股票的52周最高点是多少?
MaxCyte Inc股票的52周最高点是1.86。
MaxCyte Inc股票的52周最低点是多少?
MaxCyte Inc股票的52周最低点是0.64。
现在MaxCyte Inc(MXCT)的股票是买入、持有还是卖出?
根据分析师评级,MaxCyte Inc(MXCT)的总体评级为买入,目标价格为4.11。
MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是多少
MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是-0.37。